	Application No.	Applicant(a)
	Application No.	Applicant(s)
Notice of Allowability	10/528,461	KIM ET AL.
	Examiner	Art Unit
	Jason M. Nolan, Ph.D.	1626
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>02/28/2007</u> .		
2. 🔀 The allowed claim(s) is/are <u>1-3</u> .		
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority ur</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> </ul>	e been received.	
2. Certified copies of the priority documents have been received in Application No		
3. 🛮 Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. ☑ Notice of References Cited (PTO-892)	5. Notice of Informal F	Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Da	
3. Information Disclosure Statements (PTO/SB/08),	7. ☐ Examiner's Amendr	ment/Comment
Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
,		

Application/Control Number: 10/528,461 Page 2

Art Unit: 1626

## **DETAILED ACTION**

Claims 1-3 are pending in the instant application, all of which are currently amended. There are no new or canceled claims.

## Response to Amendment

Applicant's amendment, see Amendment – After Non-Final Rejection, filed 12/06/2006, with respect to **Claims 1-3** has been fully considered and is entered. The rejections of **Claims 1-3** are withdrawn.

## Statement of Reasons for Allowance

The present invention pertains to the pyridine described in formula I, a method of preparing formula I, and a method of using formula I for the treatment of hepatitis C. The compound according to formula I is free of the prior art; nothing known in the art anticipates or renders formula I obvious. The closest prior art related to the formula I is compound RN 470702-06-8, taught by Bryan *et al.* (US Patent 7,087,758). Compound RN 470702-06-8 contains a similar structure to formula I (a phenyl-morpholinyl-amino group at C-2 of the nitrogen heterocycle and a carboxylic acid at C-3); however, the compound is a quinoline heterocycle and formula I is a pyridine.

One skilled in the art would be enabled to make and use the compounds taught herein for the purpose of treating hepatitis C using the teachings of the Specification (background on pages 1-6; biological assays on pages 10-13: the examples establish the compositions of formula I as inhibitors on recombinant HCV RNA Polymerase *in vitro*) in conjunction with the teachings in the prior art (the review by Worman *et al. World Journal of Gastroenterology* **2000**, *6*(*4*), 465-469 supports the nexus between the inhibition of HVC RNA polymerase and the treatment of hepatitis C).

Claims 1-3 are allowed.

## Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jason M. Nolan, Ph.D.** whose telephone number is **(571) 272-4356** and electronic mail is **Jason.Nolan@uspto.gov**. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph M<sup>c</sup>Kane** can be reached on **(571) 272-0699**. The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ĵason М. Nolan, Ph.D.

Examiner Art Unit 1626 Joseph K. McKane

Supervisory Patent Examiner

Art Unit 1626

Date: March 15, 2007